Combination therapies against chronic myeloid leukemia: Short-term versus long-term strategies

Cancer Research

Volumn 69, Issue 11, 2009, Pages 4904-4910

  Komarova, Natalia L ^a   Wodarz, Dominik ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BCR ABL PROTEIN;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CHRONIC MYELOID LEUKEMIA; DRUG POTENCY; DRUG SPECIFICITY; ENZYME ACTIVITY; GENE MUTATION; PREDICTION; PRIORITY JOURNAL; STOCHASTIC MODEL; TREATMENT DURATION; TREATMENT RESPONSE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; GENES, ABL; HUMANS; KINETICS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MODELS, BIOLOGICAL; MUTATION; SUBSTRATE SPECIFICITY; TIME FACTORS; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 66349131570     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-1959     Document Type: Article

References (33)

1. Melo JV, Hughes TP, Apperley JF. Chronic myeloid leukemia. Hematology Am Soc Hematol Educ Program 2003;132-152
2. Calabretta B, Perrotti D. The biology of CML blast crisis. Blood 2004;103:4010-4022 (Pubitemid 38685338)
3. Shet AS, Jahagirdar BN, Verfaillie CM. Chronic myelogenous leukemia: mechanisms underlying disease progression. Leukemia 2002;16:1402-1411
4. Yoshida C, Melo JV. Biology of chronic myeloid leukemia and possible therapeutic approaches to imatinib-resistant disease. Int J Hematol 2004;79:420-433 (Pubitemid 38808357)
5. Jabbour E, Cortes J, O'Brien S, Giles F, Kantarjian H. New targeted therapies for chronic myelogenous leukemia: opportunities to overcome imatinib resistance. Semin Hematol 2007;44:25-31. (Pubitemid 46209244)
6. Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001;293:876-880 (Pubitemid 32743979)
7. Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004;305:399-401. (Pubitemid 38938156)
8. Daley GQ. Towards combination target-directed chemotherapy for chronic myeloid leukemia: role of farnesyl transferase inhibitors. Semin Hematol 2003;40:11-14 (Pubitemid 36687153)
9. Deininger MW, Druker BJ. Specific targeted therapy of chronic myelogenous leukemia with imatinib. Pharmacol Rev 2003;55:401-423 (Pubitemid 37013211)
10. John AM, Thomas NS, Mufti GJ, Padua RA. Targeted therapies in myeloid leukemia. Semin Cancer Biol 2004;14:41-62. (Pubitemid 38165315)
11. O'Dwyer ME, Mauro MJ, Druker BJ. Recent advancements in the treatment of chronic myelogenous leukemia. Annu Rev Med 2002;53:369-381 (Pubitemid 34177887)
12. Tauchi T, Ohyashiki K. Molecular mechanisms of resistance of leukemia to imatinib mesylate. Leuk Res 2004;28 Suppl 1:S39-45. (Pubitemid 38251497)
13. Daub H, Specht K, Ullrich A. Strategies to overcome resistance to targeted protein kinase inhibitors. Nat Rev Drug Discov 2004;3:1001-1010 (Pubitemid 39642363)
14. Druker BJ. Overcoming resistance to imatinib by combining targeted agents. Mol Cancer Ther 2003;2:225-226
15. Druker BJ. Imatinib as a paradigm of targeted therapies. Adv Cancer Res 2004;91:1-30. (Pubitemid 39140955)
16. Gambacorti-Passerini CB, Gunby RH, Piazza R, Galietta A, Rostagno R, Scapozza L. Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. Lancet Oncol 2003;4:75-85. (Pubitemid 36196725)
17. Nardi V, Azam M, Daley GQ. Mechanisms and implications of imatinib resistance mutations in BCR-ABL. Curr Opin Hematol 2004;11:35-43. (Pubitemid 38021719)
18. Shannon KM. Resistance in the land of molecular cancer therapeutics. Cancer Cell 2002;2:99-102. (Pubitemid 41039109)
19. Yee KW, Keating A. Advances in targeted therapy for chronic myeloid leukemia. Expert Rev Anticancer Ther 2003;3:295-310. (Pubitemid 36748043)
20. Bradeen HA, Eide CA, O'Hare T, et al. Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations. Blood 2006;108:2332-2338 (Pubitemid 44497517)
21. Komarova NL, Wodarz D. Stochastic modeling of cellular colonies with quiescence: an application to drug resistance in cancer. Theor Popul Biol 2007;72:523-538 (Pubitemid 47615113)
22. Komarova NL, Wodarz D. Effect of cellular quiescence on the success of targeted CML therapy. PLoS ONE 2007;2:e990.
23. Roeder I, Horn M, Glauche I, Hochhaus A, Mueller MC, Loeffler M. Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications. Nat Med 2006;12:1181-1184 (Pubitemid 44527354)
24. Michor F, Hughes TP, Iwasa Y, et al. Dynamics of chronic myeloid leukaemia. Nature 2005;435:1267-1270 (Pubitemid 40943094)
25. Komarova NL, Wodarz D. Drug resistance in cancer: principles of emergence and prevention. Proc Natl Acad Sci U S A 2005;102:9714-9719 (Pubitemid 40981746)
26. Wodarz D, Komarova NL. Emergence and prevention of resistance against small molecule inhibitors. Semin Cancer Biol 2005;15:506-514 (Pubitemid 41318049)
27. Gulick RM, Mellors JW, Havlir D, et al. Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-week follow-up. JAMA 1998;280:35-41. (Pubitemid 28414994)
28. Bonhoeffer S, May RM, Shaw GM, Nowak MA. Virus dynamics and drug therapy. Proc Natl Acad Sci U S A 1997;94:6971-6976 (Pubitemid 27281975)
29. Ribeiro RM, Bonhoeffer S. Production of resistant HIV mutants during antiretroviral therapy [see comments]. Proc Natl Acad Sci U S A 2000;97:7681-7686 (Pubitemid 30460706)
30. Ribeiro RM, Bonhoeffer S, Nowak MA. The frequency of resistant mutant virus before antiviral therapy. Aids 1998;12:461-465 (Pubitemid 28116154)
31. Carter TA, Wodicka LM, Shah NP, et al. Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc Natl Acad Sci U S A 2005;102:11011-11016
32. Quintas-Cardama A, Kantarjian H, Cortes J. Flying under the radar: the new wave of BCR-ABL inhibitors. Nat Rev Drug Discov 2007;6:834-848 (Pubitemid 47500507)
33. Goldie JH, Coldman AJ. Drug resistance in cancer: mechanisms and models. Cambridge (UK): Cambridge University Press; 1998.